Skip to content

Category: General

Stem-Cell Therapy Clinics Remain Inadequately Regulated, Pose Risk to Patients

Source: Foundation Fighting Blindness Blog – Eye on the Cure – Stem-Cell Therapy Clinics Remain Inadequately Regulated, Pose Risk to Patients Though the U.S. Food & Drug Administration (FDA) is more tightly regulating U.S. clinics that tout stem-cell trials and treatments for inherited retinal diseases (IRDs) and a host…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

ProQR Doses First Participant in Its LCA10 Therapy Clinical Trial

Source: Foundation Fighting Blindness Blog – Eye on the Cure – ProQR Doses First Participant in Its LCA10 Therapy Clinical Trial ProQR, a biotech company in the Netherlands, has treated its first patient in a Phase 1/2 clinical trial for QR-110, a therapy for people with Leber congenital amaurosis…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

FDA Committee Unanimously Recommends Approval for Spark’s RPE65 Gene Therapy – Final Decision Due in January 2018

Source: Foundation Fighting Blindness Blog – Eye on the Cure – FDA Committee Unanimously Recommends Approval for Spark’s RPE65 Gene Therapy – Final Decision Due in January 2018 Ashley and Cole Carper traveled from Little Rock, AR, to tell their family’s story at the FDA hearing. Spark Therapeutics has…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

FFB’s Investments Are Filling the Pipeline for Vision-Saving Therapies

Source: Foundation Fighting Blindness Blog – Eye on the Cure – FFB’s Investments Are Filling the Pipeline for Vision-Saving Therapies With five gene-therapy clinical trials underway or soon to begin, Applied Genetic Technologies Corporation (AGTC) is generating tremendous excitement for the potential to overcome vision loss from several inherited…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

MeiraGTx Treats First Patient in XLRP Gene-Therapy Trial

Source: Foundation Fighting Blindness Blog – Eye on the Cure – MeiraGTx Treats First Patient in XLRP Gene-Therapy Trial MeiraGTx, a gene-therapy company in London and New York City, has treated its first patient in a gene-therapy clinical trial for people with X-linked retinitis pigmentosa (XLRP) caused by mutations…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest